An observational study in Inflammatory Bowel Diseases and Crohn Disease, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 19 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by University of British Columbia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Crohn Disease by University of British Columbia — 5 open to participants now, 5 under way, none of them phase 3. Crohn Disease · University of British Columbia.
Among the 13 studies in Crohn Disease by University of British Columbia, this one is the only one that started in 2024, is one of 7 observational ones, and was the 10th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →5 of the 13 studies in Crohn Disease by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Ages 9–17
University of British Columbia · Sites in Canada
Ages 19+ · Women only · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 18+ · Healthy volunteers
University of British Columbia
Ages 19+
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 19 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 184 across 646 observational studies indexed under Crohn Disease.
Median enrollment 71 across the 6 interventional studies, 95 across the 7 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
2 of the studies in Crohn Disease by University of British Columbia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07814274University of British ColumbiaProspective Intestinal Ultrasound Study for Artificial Intelligence Algorithm Development | 2027-02-01 |
| NCT06109961University of British ColumbiaHyperbaric Oxygen Therapy for Perianal Fistulizing Crohn's Disease Not Responsive or Intolerant to Conventional Care: HYPNOTIC Pilot Study | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Crohn Disease by University of British Columbia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this prospective observational study is to determine if specific microbiome signatures can predict therapeutic responses in adult patients with Crohn's disease (CD), a form of inflammatory bowel disease (IBD), living in British Columbia, Canada. The main questions this study seeks to answer are:
Researchers will compare microbiome signatures in patients with active and inactive CD as well as non-IBD controls to see if there are any microbial signatures that predict response to therapy.
Participants will:
Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition affecting the gastrointestinal (GI) tract. The study aims to evaluate microbiome profiles (bacteriome, and mycobiome) across three different sample types (fecal, intestinal washings, and intestinal epithelial biopsies) in a cohort of adult patients with Crohn's disease (CD) living in British Columbia, Canada, and investigate whether a microbial signature may predict response to IBD therapy.
Aims:
Methods
Study Design:
Phase 1: A cross-sectional pilot study to evaluate the microbiome in patients with IBD (with active and quiescent disease) and in non-IBD controls.
Primary Outcome: Compare results of microbial analyses (including bacteriome and mycobiome) across three different sample types: intestinal washings and intestinal epithelial biopsy specimens taken during colonoscopy, as well as fecal samples.
Secondary Outcomes: Investigate correlations between the microbial analyses across different sample types and disease activity in CD. Compare the difference in microbial analyses within each sample type between active and quiescent CD as well as non-IBD patients. Investigate if fecal microbiome composition and function 2 weeks after bowel preparation is comparable to pre-bowel preparation fecal microbiome in a subset of patients with CD.
Phase 2: A longitudinal observational study with a 12-month follow-up.
Primary Outcome: Identify if there are any microbial signatures that predict response to therapy in patients with active disease requiring escalated therapy, assessed clinically and biochemically after induction (12-16 weeks) and at 12 months (+/- 3 months).
Secondary Outcomes: Compare the sensitivity and specificity of microbial analyses from each sample type in predicting response to therapy.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
This study's planned enrollment of 100 is below the median of 184 across 646 observational studies indexed under Crohn Disease.
Browse Crohn Disease studies →University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Compared within Crohn Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The investigators aim to have 75 CD patients complete phase 1 and 2, and 25 non-IBD controls to complete phase 1 only.
Patient grouping for recruitment is as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
CD patients:
Non-IBD controls:
Exclusion Criteria:
CD patients:
Non-IBD controls:
The study will include 75 consenting patients with Crohn's disease, varying in levels of severity depending on assigned SES-CD scoring from their gastroenterologist. These patients will be undergoing routine colonoscopy as per their normal care routine, with this study not requiring additional scheduling commitments. Blood, mucosal washing, and intestinal biopsy samples will be collected during routine colonoscopy procedure. The patient will have the option to collect a stool sample the day before their colonoscopy and bring it to their appointment. They will also receive a sample collection kit during their appointment to collect their next required stool sample in two weeks after their scope.
Procedure: Colonoscopy
The study will include 25 non-IBD age and sex-matched controls to compare data alongside the CD patients. These patients will be undergoing routine colonoscopy as per their normal colon screening routine, with this study not requiring additional scheduling commitments. Blood, mucosal washing, and intestinal biopsy samples will be collected during routine colonoscopy procedure. The patient will have the option to collect a stool sample the day before their colonoscopy and bring it to their appointment. They will also receive a sample collection kit during their appointment to collect their next required stool sample in two weeks after their scope.
Procedure: Colonoscopy
A colonoscopy will be performed as part of routine clinical care for all participants, with the study not requiring any additional scheduling commitments outside of routine care.
Compare results of microbial analyses (including bacteriome and mycobiome) across three different sample types: intestinal washings and intestinal epithelial biopsy specimens taken during colonoscopy as well as fecal samples.
Microbial analyses that will be undertaken for each sample type are as follows: Stool: * Metagenomics (Shotgun sequencing, ITS sequencing for fungal analysis) * Metaproteomics and metabolomics (Host, microbial, and dietary protein analysis, microbial metabolite analysis) * Anaerobic culturing (Simulate gut environment, use dietary substrates to target key microbes) Biopsy specimens: * Organoid culturing (In vitro gut model analysis, epithelial-microbiome analysis, mucin production analysis) * RNA-seq, transcriptomics (Gene expression profiling analysis, disease marker identification) * Metagenomics * Metaproteomics and metabolomics Intestinal washings: * Mucin analysis (Glycoprotein analysis) * Metagenomics * Metaproteomics and metabolomics
Time frame: 24 months
In patients with active Crohn's disease, where a decision is made to escalate therapy after the index endoscopy, identify if there are any microbial signatures that predict response to therapy after induction (12 - 16 weeks).
* Clinical Response: Defined based on changes in clinical symptoms as per standardized clinical scoring systems (SES-CD). * Biochemical Response: Assessed through C-reactive protein (CRP) levels and fecal calprotectin, two biomarkers that indicate inflammation or disease activity. The Simple Endoscopy Score for Crohn's Disease (SES-CD) is an objective clinical assessment of the severity of a patient's Crohn's disease. A higher score means more severe disease activity. The three severity classes of SES-CD scoring are as follows: * Endoscopic remission (SES-CD \<3). * Moderate to severe endoscopically active disease (SES-CD ≥ 7 or ≥ 4 for isolated ileal CD). * Mild endoscopically active disease (SES-CD of 3-6, or 3 with isolated ileal CD).
Time frame: 24 months
In patients with active Crohn's disease, where a decision is made to escalate therapy after the index endoscopy, identify if there are any microbial signatures that predict sustained response to therapy at 12 Months (+/- 3 months).
* Clinical Response: Continuation or improvement in clinical symptoms as measured by standardized clinical scoring systems (SES-CD). * Biochemical Response: Persistent normalization or improvement in CRP levels and fecal calprotectin. * Endoscopic Response: Improvement or healing of mucosal lesions as observed during endoscopic examination, assessed by validated clinical scoring systems (SES-CD).
Time frame: 24 months
Investigate the correlations between the microbial analyses across different sample types and disease activity in CD.
Correlation Analysis: Statistical measures will be used to assess the strength and direction of the relationship between microbial composition in different sample types (intestine washings, intestinal biopsy, fecal samples) and disease activity in CD. Disease Activity Measures: Disease activity will be assessed using the modified Harvey-Bradshaw Index, biochemical markers (CRP, fecal calprotectin), and endoscopic findings (SES-CD).
Time frame: 24 months
Compare the difference in microbial analyses within each sample type between active and quiescent CD as well as non-IBD patients.
Assessments: 1\. Microbial Diversity Metrics: * Alpha-diversity Metrics: * Shannon index * Inverse Simpson diversity index * Chao1 * These metrics will be used to compare microbial diversity within each sample type between active and quiescent CD patients, as well as non-IBD patients.
Time frame: 24 months
Compare the difference in microbial analyses within each sample type between active and quiescent CD as well as non-IBD patients.
Assessments: Differential Abundance Analysis: Differential abundance analysis will be performed using generalized linear models to identify specific microbial taxa that are significantly different between active and quiescent CD patients, and non-IBD patients within each sample type.
Time frame: 24 months
Investigate, in a subset of patients with CD, if fecal microbiome composition and function 2 weeks after bowel preparation is comparable to pre-bowel preparation fecal microbiome.
Assessments: Comparison of Microbial Composition: Beta-diversity metrics (Bray-Curtis dissimilarity, Jaccard index) and phylogenetic-dependent distance metrics (weighted and unweighted UniFrac) will be calculated, and subsequent clustering will be applied using a principal coordinate analysis (PCoA). To test for overall microbiome differences, a PERMANOVA test will be applied. The Benjamini-Hochberg method will be applied to control for the false discovery rate.
Time frame: 24 months
Investigate, in a subset of patients with CD, if fecal microbiome composition and function 2 weeks after bowel preparation is comparable to pre-bowel preparation fecal microbiome.
Assessments: Functional Analysis: Functional profiling of the microbiome will be conducted to assess if there are any changes in the metabolic pathways and functions of the microbiome between pre- and post-bowel preparation samples in the subset of CD patients.
Time frame: 24 months
Compare the sensitivity of the microbial analyses from each sample type in their prediction of response to therapy.
Sensitivity of Microbial Analyses: * Using predictive models developed from microbial and statistical analyses, the sensitivity of microbial analyses from each sample type will be evaluated. * Sensitivity will be reported as the proportion of true positives correctly identified by the analysis.
Time frame: 24 months
Compare the specificity of the microbial analyses from each sample type in their prediction of response to therapy.
Specificity of Microbial Analyses: * Predictive models will also be used to evaluate the specificity of microbial analyses from each sample type. * Specificity will be reported as the proportion of true negatives correctly identified by the analysis.
Time frame: 24 months
Started Aug 2024 (actual). Primary completion is estimated for Jul 2026, 23 months after the start.
Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's planned 23 months is below that.
Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →